title: Medtronic Mosaic porcine bioprosthesis: assessment of 12-year performance.
abstract: BACKGROUND
  The Mosaic porcine bioprosthesis (Medtronic, Inc, Minneapolis, Minn) was approved in 2000 by the US Food and Drug Administration. Clinical performance was evaluated in 6 centers.
  
  
  METHODS
  From 1994 to 2000, 797 patients (mean age 69 years) had aortic valve replacement (AVR) and 232 (mean 67 years) had mitral valve replacement (MVR). Concomitant coronary artery bypass grafting was performed with aortic valve replacement (45.4%) and mitral valve replacement (43.5%). Mean follow-ups were 7.5 years for aortic position and 7.3 years for mitral position.
  
  
  RESULTS
  Early mortalities were 2.8% for AVR and 3.0% for MVR. Late mortalities were 4.2%/patient-year for AVR and 5.1%/patient-year for MVR. Overall 12-year survivals were 55.8% ± 3.7% for AVR and 43.9% ± 7.4% for MVR. Twelve-year freedoms from valve-related mortality were 87.1% ± 3.1% for AVR and 82.5% ± 7.7% for MVR. Twelve-year freedoms from reoperation were 84.0% ± 3.3% for AVR and 82.5% ± 7.5% for MVR. Freedoms from structural valve deterioration (SVD) by explant reoperation at 12 years for AVR were 93.3% ± 2.6% for patients at least 60 years old and 75.9% ± 9.3% for patients younger than 60 years. Freedoms from SVD by explant reoperation at 10 years for MVR were 95.3% ± 7.8% for patients at least 70 years old and 84.0% ± 9.3% for patients younger than 70 years. Hemodynamic performance data at 1 year for AVR (sizes 21-27 mm) were mean systolic gradient range 13.7 ± 4.8 to 10.3 ± 3.2 mm Hg and effective orifice area range 1.5 ± 0.3 to 2.5 ± 0.4 cm(2). For MVR (sizes 25-31 mm), data were mean diastolic gradient range 6.7 ± 1.7 to 3.7 ± 0.9 mm Hg and effective orifice area range 1.9 ± 0.3 to 2.4 ± 0.6 cm(2).
  
  
  CONCLUSIONS
  Overall performance of Mosaic porcine bioprosthesis to 12 years is satisfactory. Freedoms from SVD by explant reoperation were most satisfactory for aortic position in patients at least 60 years old and mitral position in patients at least 70 years old. Overall actuarial freedom from SVD by explant reoperation is encouraging for patients with MVR.
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada. eric.jamieson@vch.ca
authors.forename: W R Eric
authors.initials: WR
authors.lastname: Jamieson
authors.forename: Friedrich-Christian
authors.initials: FC
authors.lastname: Riess
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Raudkivi
authors.forename: Jacques
authors.initials: J
authors.lastname: Metras
authors.forename: Edward F G
authors.initials: EF
authors.lastname: Busse
authors.forename: Jacob
authors.initials: J
authors.lastname: Goldstein
authors.forename: Guy J
authors.initials: GJ
authors.lastname: Fradet
mesh_terms: D000368:Aged; D001021:Aortic Valve; D001705:Bioprosthesis / Q000592:standards*; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000592:standards*; D006801:Humans; D008875:Middle Aged; D008943:Mitral Valve; D012086:Reoperation